Table 5. Comparison of perfusion values between GBM patients with different statuses of 2-year survival.
| Perfusion values | 2-year survival | P value | |
|---|---|---|---|
| < 2 year (n = 25) | > 2 year (n = 5) | ||
| rCBVmean of nonenhanced tumor (ratio) | 2.70 +/- 1.15 | 1.32 +/- 1.87 | 0.152 |
| rCBVmean of enhanced tumor (ratio) | 3.90 [3.15–4.70] | 4.75 [3.35–5.19] | 0.675 |
| rCBVmean of whole tumor (ratio) | 3.63 [2.70–4.39] | 4.75 [3.35–4.76] | 0.436 |
| rCBV5%max (ratio) | 9.44 [6.83–11.22] | 10.20 [9.61–10.31] | 0.911 |
| rCBV10%max (ratio) | 7.91 [6.27–9.91] | 9.31 [8.12–9.41] | 1.000 |
| rCBVhigh_perfusion (ratio) | 7.11 [5.55–10.39] | 6.32 [6.04–7.42] | 0.578 |
| rCBVvariation_mean of nonenhanced tumor | 13.02 [8.58–22.83] | 12.65 [12.65–12.65] | 1.000 |
| rCBVvariation_mean of enhanced tumor | 17.24 [12.17–22.95] | 8.82 [7.32–24.34] | 0.675 |
| rCBVvariation_mean of whole tumor | 18.89 [8.52–20.76] | 22.37 [22.37–22.37] | 0.335 |
| rCBVvariation_max of nonenhanced tumor | 46.87 [24.09–72.13] | 22.45 [22.45–22.45] | 0.386 |
| rCBVvariation_max of enhanced tumor | 63.35 +/- 32.30 | 42.62 +/- 16.83 | 0.179 |
| rCBVvariation_max of whole tumor | 61.76 +/- 32.69 | 42.62 +/- 16.83 | 0.217 |
Note: values are the mean +/- standard deviation or the median and [first quartile—third quartile]. P values were calculated by using two sample t test or non-parametric Wilcoxon rank sum test when normality assmption was not met. rCBVmean, mean rCBV; rCBV5%max, 5% maximum rCBV; rCBV10%max, 10% maximum rCBV; rCBVhigh_perfusion, maximum rCBV; rCBVvariation_mean, mean rCBV variation; rCBVvariation_max, maximum rCBV variation.